326 related articles for article (PubMed ID: 27288871)
1. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
2. Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
Paajanen J; Ilonen I; Lauri H; Järvinen T; Sutinen E; Ollila H; Rouvinen E; Lemström K; Räsänen J; Ritvos O; Koli K; Myllärniemi M
Clin Lung Cancer; 2020 May; 21(3):e142-e150. PubMed ID: 31734071
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
[TBL] [Abstract][Full Text] [Related]
4. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
Ghanim B; Hoda MA; Klikovits T; Winter MP; Alimohammadi A; Grusch M; Dome B; Arns M; Schenk P; Jakopovic M; Samarzija M; Brcic L; Filipits M; Laszlo V; Klepetko W; Berger W; Hegedus B
Br J Cancer; 2014 Feb; 110(4):984-90. PubMed ID: 24434429
[TBL] [Abstract][Full Text] [Related]
5. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
6. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
[TBL] [Abstract][Full Text] [Related]
7. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
8. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
10. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
12. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
[TBL] [Abstract][Full Text] [Related]
13. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
14. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Dome B; Renyi-Vamos F; Oehler R; Hegedus B
Sci Rep; 2017 Nov; 7(1):16456. PubMed ID: 29184132
[TBL] [Abstract][Full Text] [Related]
15. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
[TBL] [Abstract][Full Text] [Related]
16. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
Yoneda K; Kuwata T; Chikaishi Y; Mori M; Kanayama M; Takenaka M; Oka S; Hirai A; Imanishi N; Kuroda K; Ichiki Y; Ohnaga T; Tanaka F
Cancer Sci; 2019 Feb; 110(2):726-733. PubMed ID: 30499156
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]